Boost Life Sciences Innovation and Patient Control
Labour · what the evidence says
An independent, source-checked look at Labour’s policy “Boost Life Sciences Innovation and Patient Control” — what it would actually do across the things that affect your life. Every claim below quotes the source behind it. How this works.
Prosperity & living standards — Genuinely contested
n/a · low confidence
This policy could boost UK life sciences by fixing slow clinical-trial set-up and NHS procurement barriers, which would support investment and productivity. But the commitments are aspirational — no budgets or statutory targets — and the NHS has a well-documented history of failing to scale exactly these kinds of reforms.
The evidence
- The policy commits to developing an NHS innovation and adoption strategy with reformed procurement and incentive structures to accelerate new technology and medicines. — labour.org.uk (manifesto) — “develop an NHS innovation and adoption strategy, including a plan for procurement and reformed incentive structures, to accelerate new technology and medicines into the NHS”
- The policy aims to maximise UK potential in clinical trials by making the process more efficient through the NHS app. — labour.org.uk (manifesto) — “maximise UK potential in clinical trials by making the process more efficient and accessible through the NHS app”
- UK clinical trial activity has been declining — patient entry into UK clinical trials fell 27% between 2018 and 2023, with new industry trials declining 38%. — theguardian.com (media) — “patient entry into UK clinical trials fell by 27% between 2018 and 2023, with new industry trials declining by 38%”
- NHS clinical trial set-up is slow relative to international comparators — it takes about 250 days to set up a trial in the NHS, compared to 100 days in Spain. — pslhub.org (media) — “it takes about 250 days to set up a trial in the NHS, compared to 100 days in Spain”
- The life sciences sector's collaboration with the NHS attracted foreign direct investment exceeding £1.3 billion in 2022, showing genuine economic significance. — england.nhs.uk (media) — “substantial foreign direct investment, exceeding £1.3 billion in 2022”
- The global clinical trials market is estimated to be worth at least $80 billion by 2030, meaning improved UK competitiveness here could yield material economic gains. — gov.uk (media) — “the global clinical trials market estimated to be worth at least $80 billion by 2030”
- Only 28% of digital health innovators had successfully procured and scaled their products across the NHS, indicating deep structural barriers. — uclpartners.com (media) — “only 28% of digital health innovators interviewed had successfully procured and scaled their products across the NHS”
- Barriers to NHS innovation adoption include fragmented regulation, slow procurement processes, and limited support and incentives for NHS staff. — uclpartners.com (media) — “Barriers include fragmented regulation, slow procurement processes, and limited support and incentives for NHS staff”
- Procurement reform faces deep complexity — the Nuffield Trust notes an overly supply-driven and top-down approach to innovation in the NHS, and reform requires overcoming market failures and shifting to value-based payment approaches. — mtg.org.uk (media) — “Reform would need to overcome these issues, ensure demand for innovative products, and support value-based payment approaches”
Biggest unknown: Whether procurement and incentive reforms will actually be legislated and funded at scale, or remain pilots and strategies on paper as has historically happened with NHS innovation programmes.
Our reading: The economic case for this policy is real in principle. The UK's clinical trial competitiveness is measurably declining, set-up times are more than twice as long as Spain's, and only a fraction of health innovators successfully scale through the NHS. The life sciences sector already attracts over £1.3bn in FDI annually, and the global clinical trials market is large and growing. If the policy delivered on procurement reform and trial streamlining, it could plausibly reverse decline in this sector and support productivity and business investment — directly relevant to O13. However, the threshold discipline cuts hard here. The policy commits to 'developing a strategy' and 'maximising potential' — soft verbs with no committed budget, no statutory duty, no quantified target. The NHS has a documented, evidence-backed history of exactly this failure mode: promising pilots that fail to scale, innovation strategies that don't change procurement behaviour on the ground, and IT transformation projects that run into interoperability and change-management barriers. The Nuffield Trust flags an overly top-down approach; the UCLPartners data on 'pilotitis' and the 28% scaling rate confirm this is a structural problem, not a marginal one. The life sciences angle is the most credible path to O13 gains — but whether this policy delivers depends entirely on whether the strategy is backed by real instruments. Without evidence that it will be, the verdict cannot be 'improves': mechanism plausibility is not effect. The genuine uncertainty between 'material O13 improvement if delivered' and 'near-zero effect if another strategy document' makes this too-uncertain.
Healthcare — Mixed picture
minor · low confidence
This policy aims to speed up new treatments reaching patients and make the NHS app a hub for managing health needs, but it is built on strategies and aspirations rather than committed budgets or statutory duties, and faces well-documented barriers around digital exclusion, procurement complexity, and NHS IT delivery history. Some people — especially those without smartphones or digital skills — could find themselves worse served if app-centric access crowds out other routes.
The evidence
- The policy commits to developing an NHS innovation and adoption strategy with reformed procurement and incentive structures to accelerate new technology and medicines. — labour.org.uk (manifesto) — “Labour will develop an NHS innovation and adoption strategy, including a plan for procurement and reformed incentive structures, to accelerate new technology and medicines into the NHS”
- The policy commits to transforming the NHS app so patients can manage medicines, appointments, and health needs and access performance information. — labour.org.uk (manifesto) — “The NHS app will also be transformed to put patients in control of their health, allowing management of medicines, appointments, and health needs, including access to performance information and medical guidelines”
- The NHS app already has very large existing reach, with over 39 million registered users as of December 2025. — england.nhs.uk (media) — “The NHS App already has over 39 million registered users (as of December 2025), with 62.3 million logins in November 2025 alone”
- UK clinical trial activity has declined sharply, with patient entry into trials falling 27% between 2018 and 2023. — theguardian.com (media) — “patient entry into UK clinical trials fell by 27% between 2018 and 2023, with new industry trials declining by 38%”
- NHS trial set-up takes around 250 days, compared to 100 days in Spain, making the UK less competitive for trials. — pslhub.org (media) — “it takes about 250 days to set up a trial in the NHS, compared to 100 days in Spain”
- Only 28% of digital health innovators had successfully procured and scaled their products across the NHS, pointing to systemic procurement failure. — uclpartners.com (media) — “only 28% of digital health innovators interviewed had successfully procured and scaled their products across the NHS”
- Barriers to NHS innovation adoption include fragmented regulation, slow procurement, and limited incentives for NHS staff. — uclpartners.com (media) — “Barriers include fragmented regulation, slow procurement processes, and limited support and incentives for NHS staff”
- Around 23% of people rarely or never use the NHS app due to technical barriers, and over a third prefer speaking to a person. — patients-association.org.uk (media) — “23% of people rarely or never used it due to technical reasons (e.g., lack of smartphone access, difficulty downloading/registering)”
- Over a third of app users could not access test results or personal health records because GP practices had not made them accessible. — patients-association.org.uk (media) — “over one-third of app users couldn't access key information like test results (39%) or personal health records (36%) because some GP practices had not made them accessible”
- Faster adoption of new treatments could mean patients receive cutting-edge care years earlier. — gov.uk (media) — “Accelerating the adoption of new technologies and medicines could mean patients receive cutting-edge treatments years earlier”
- Achieving a single patient record across the NHS faces historical challenges integrating disparate IT systems. — theguardian.com (media) — “Achieving a "single patient record" across the entire NHS, as Labour plans, faces historical challenges with integrating disparate IT systems”
- Technology alone will not resolve NHS bottlenecks and risks digitising inefficiencies without strong change management. — digitalhealth.net (media) — “Digital transformation must be accompanied by strong change management, workforce training, and user-centred design, otherwise, the NHS risks "digitising existing inefficiencies rather than redesigning care around the ne…”
- The Nuffield Trust notes an overly supply-driven and top-down approach to innovation in the NHS as a structural barrier to reform. — nuffieldtrust.org.uk (institutional) — “The Nuffield Trust notes an "overly supply-driven and top-down approach to innovation" in the NHS”
Biggest unknown: Whether the 'NHS innovation and adoption strategy' and app transformation will come with the funding, change management, and interoperability fixes needed to overcome the NHS's long record of failed IT ambitions — or remain high-level intentions.
Our reading: This policy targets two genuine pressure points for O3: the slow uptake of treatments into the NHS, and friction patients face accessing appointments and managing care. Both are real problems — clinical trial participation has fallen sharply, trial set-up times are more than twice as slow as comparable countries, and only a minority of digital health innovators manage to scale their products in the NHS. App usage is already large, giving the digital channel real reach. However, the policy is dominated by soft verbs ('will develop a strategy', 'will be transformed') with no committed budget, statutory duty, or quantified delivery target in the stated text. The threshold rule therefore requires caution: strategies are not delivered outcomes. History is littered with NHS IT transformation announcements that did not materialise at scale — single patient records, procurement reform, and innovation adoption have all been attempted before. On the upside: if the strategy delivers reformed procurement and incentive structures, there is a plausible mechanism by which new medicines and technologies reach patients faster, improving access and outcomes. If trial set-up times genuinely fall, more patients can access novel treatments earlier. These are real O3 gains — but they are conditional on implementation. On the downside: digital exclusion is a real and documented concern. Around a quarter of the public rarely or never use the app for technical reasons; a third prefer talking to a person; and over a third of existing users cannot access key health data because GP practices have not enabled it. A strategy that concentrates access through the app without fixing interoperability and without maintaining non-digital routes risks reducing access for already-disadvantaged groups — a direct O3 harm. The verdict is therefore mixed at minor magnitude. There are genuine, evidence-supported upsides and genuine, evidence-supported downsides. Confidence is low because delivery is contingent on overcoming procurement, interoperability, and change-management barriers that have historically blocked similar ambitions.